Recap: Myovant Sciences Q2 Earnings

Shares of Myovant Sciences MYOV rose 0.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 5.06% over the past year to ($0.75), which missed the estimate of ($0.73).

Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $290,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Myovant Sciences hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 12, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/mkxeraxu

Technicals

Company's 52-week high was at $23.04

Company's 52-week low was at $5.39

Price action over last quarter: down 0.84%

Company Profile

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.